Search

Displaying results 2551 - 2560 of 8974 in total
  1. Drug

    Cladribine

    go.drugbank.com/drugs/DB00242
    ApprovedInvestigational

    Cladribine is a purine analogue or a chlorinated derivative of adenine [A263733] that causes apoptosis of B and T lymphocytes. … [A350] Cladribine was first approved in the United States in 1993 [A263713] initially as a treatment for a number of hematological malignancies; currently, it is approved for the treatment of hairy cell

  2. Drug

    Idoxuridine

    go.drugbank.com/drugs/DB00249
    ApprovedWithdrawn

    An analog of deoxyuridine that inhibits viral DNA synthesis. The drug is used as an antiviral agent.

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  3. Drug

    Cefroxadine

    go.drugbank.com/drugs/DB11367
    ApprovedWithdrawn

    As part of its drug class, it shares structural properties to [cefalexin] as well as its activity spectrum. It was used in Italy but has since been withdrawn.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  4. Drug

    Tipiracil

    go.drugbank.com/drugs/DB09343
    ApprovedInvestigational

    It is used in combination with trifluridine, in a ratio of 1:0.5, to form TAS-102. The main function of Tipiracil in TAS-102 is to increase trifluridine bioavailability by inhibiting its catabolism. … [A31255] TAS-102 is indicated for the treatment of metastatic colorectal cancer which has been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, or with an anti-VEGF

  5. Drug

    Alfuzosin

    go.drugbank.com/drugs/DB00346
    Approved

    The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over 70. … Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow.

    Products: Alfuzosin PH&T 10mg prolonged-release tablets
  6. Indication

    Letterer-Siwe disease

    go.drugbank.com/conditions/DBCOND0021755
    Drugs: Vinblastine
    Synonyms: Langerhans cell histiocytosis, no International Classification of Diseases for Oncology subtype
  7. Indication

    Lymphoma, Diffuse

    go.drugbank.com/conditions/DBCOND0036855
    Drugs: Chlorambucil · Daunorubicin · Mechlorethamine
    Synonyms: Non-Hodgkin lymphoma, no International Classification of Diseases for Oncology subtype
  8. Indication

    Non-Hodgkin's Lymphoma (NHL)

    go.drugbank.com/conditions/DBCOND0030854
    Drugs: Bleomycin · Chlorambucil · Cladribine · Cyclophosphamide · Cytarabine · Daunorubicin +8 more
    Synonyms: Non-Hodgkin lymphoma, no International Classification of Diseases for Oncology subtype
  9. Drug

    Atrasentan

    go.drugbank.com/drugs/DB06199
    ApprovedInvestigational

    to be approved for this condition. … [L52855] In April 2025, atrasentan was granted accelerated approval by the FDA for the reduction of proteinuria in patients with primary IgA nephropathy, becoming the first endothelin A receptor antagonist

  10. Drug

    Atomoxetine

    go.drugbank.com/drugs/DB00289
    ApprovedInvestigational

    [A178090] Atomoxetine has been shown to specifically increase NA and DA within the prefrontal cortex, but not in the nucleus accumbens (NA) or striatum. … The non-stimulant norepinephrine/dopamine reuptake inhibitor [DB01156] (commonly used for the treatment of depression and for smoking cessation) has also been shown to be effective in the treatment of

    Categories: Psychostimulants, Agents Used for ADHD and Nootropics